Statins, regulatory T cells, and pediatric graft coronary artery disease

Pediatric Transplantation

Volumn 13, Issue 1, 2009, Pages 139-140

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^a  

^a Comando Brigata Alpina Julia ^*

^b Medical Service   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSCRIPTION FACTOR FOXP3;

CANCER IMMUNOTHERAPY; CANCER RISK; CHILD CARE; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG MEGADOSE; GRAFT REJECTION; HUMAN; LETTER; LIVER GRAFT; LOW DRUG DOSE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

CHILD; CORONARY ARTERY DISEASE; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; T-LYMPHOCYTES, REGULATORY;

EID: 58149287906     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00995.x     Document Type: Letter

References (19)

1. Chin C, Lukito SS, Shek J, Bernstein D, Perry SB. Prevention of pediatric graft coronary artery disease: Atorvastatin. Pediatr Transplant 2008 : 12 : 442 446.
2. Kobashigawa JA. Potential immunosuppressive effects of statins. Pediatr Transplant 2008 : 12 : 381 384.
3. + T cells. Atherosclerosis 2008 : 197 : 829 839.
4. Goldstein MR, Mascitelli L, Pezzetta F. Statins, Tregs and cancer. Atherosclerosis 2008 : 196 : 483 484.
5. + cells accompany allograft rejection in pediatric liver allograft recipients. Pediatr Transplant 2009 : 13 : 70 80.
6. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T cell responses: Potential role in the control of atherosclerosis. Curr Opin Lipidol 2005 : 16 : 518 524.
7. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007 : 117 : 1167 1174.
8. Yakirevich E, Resnick MB. Regulatory T lymphocytes: Pivotal components of the host antitumor response. J Clin Oncol 2007 : 25 : 2506 2508.
9. Bates GJ, Fox SB, Han C. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006 : 24 : 5373 5380.
10. +CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006 : 177 : 7398 7405.
11. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 : 10 : 942 949.
12. - T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006 : 67 : 1 12.
13. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007 : 50 : 409 418.
14. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of aging. J Pathol 2007 : 211 : 144 156.
15. Shepherd J, Blauw GJ, Murphy MB, et al, On behalf of the prosper Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002 : 360 : 1623 1630.
16. Sacks FM, Pfeffer MA, Moye LA, et al, On behalf of the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 : 335 : 1001 1009.
17. Ford I, Murray H, Packard CJ, et al, On behalf of the West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007 : 357 : 1477 1486.
18. Wenger NK, Lewis SJ, Herrington DM, et al, On behalf of the Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007 : 147 : 1 9.
19. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006 : 355 : 2705 2707.